PCM
CODX

Prelude Capital Management’s Co-Diagnostics CODX Stock Holding History

Prelude Capital Management’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-197
Closed -$114K – 1894
2020
Q2 		$114K Buy
197
+154
+358% +$70.3K 0.01% 905
2020
Q1 		$10K Buy
+43
New +$7.46K ﹤0.01% 1126

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prelude Capital Management's CODX Position: Q2 2022 in Review

Prelude Capital Management sold out of Co-Diagnostics (CODX) in Q2 2022, closing a stake of 573 shares — an estimated $106K sold.

Prelude Capital Management first reported a position in CODX in Q2 2020 and held it in 2 quarters. The position peaked at $106K in Q1 2022. 69 funds tracked by Wall St. Rank hold CODX as of Q2 2022.

  • Prelude Capital Management reported no remaining Co-Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Prelude Capital Management sold 573 Co-Diagnostics shares in Q2 2022, an estimated $106K.
  • Prelude Capital Management first reported a position in Co-Diagnostics in Q2 2020 and held it in 2 quarters.
  • Prelude Capital Management's Co-Diagnostics position peaked at $106K in Q1 2022.
  • 69 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2022.

Based on Prelude Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.